No takes yet. Share an insight, caveat, or question.
Cross-sectional analysis reveals high CLDN18.2 expression with minimal HER2 overlap in gastric cancer, highlighting its potential as an independent therapeutic target.
Moran et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: